Patents Assigned to Io Therapeutics, Inc.
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 9877941
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: January 30, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of cancer with specific RXR agonists
    Patent number: 9717702
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: August 1, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 9655872
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 23, 2017
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Treatment of cancer with specific RXR agonists
    Patent number: 9308186
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: April 12, 2016
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • Use of a RAR antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects
    Patent number: 9271946
    Abstract: A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RAR?, RAR? and RAR? subtypes is disclosed. Such side effects include chemoradiotherapy-induced alopecia, chemoradiotherapy-induced thrombocytopenia, chemoradiotherapy-induced leucopenia and chemoradiotherapy-induced neutropenia.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: March 1, 2016
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Yang-Dar Yuan
  • Treatment of Graft-Versus-Host Disease Disorders using RAR Antagonists
    Publication number: 20140194517
    Abstract: The present specification provides RAR antagonist compounds, compositions comprising such RAR antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RAR antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicants: Io Therapeutics, Inc., The Regents of the University of Minnesota
    Inventors: Bruce Blazer, Kazutoshi Aoyama, Roshantha Chandraratna
  • AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
    Publication number: 20130190395
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: December 13, 2012
    Publication date: July 25, 2013
    Applicants: Dartmouth College, IO Therapeutics, Inc.
    Inventors: IO Therapeutics, Inc., Dartmouth College
  • Treatment of cancer with specific RXR agonists
    Patent number: 8101662
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: January 24, 2012
    Assignee: Io Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna